Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-058060
Filing Date
2025-04-24
Accepted
2025-04-24 16:15:17
Documents
25
Period of Report
2025-04-23

Document Format Files

Seq Description Document Type Size
1 DEF 14A sage-20250421.htm   iXBRL DEF 14A 4263754
2 GRAPHIC img95046853_0.jpg GRAPHIC 36134
3 GRAPHIC img95046853_1.jpg GRAPHIC 32007
4 GRAPHIC img95046853_2.jpg GRAPHIC 36134
5 GRAPHIC img95046853_3.jpg GRAPHIC 18802
6 GRAPHIC img95046853_4.jpg GRAPHIC 16153
7 GRAPHIC img95046853_5.jpg GRAPHIC 19283
8 GRAPHIC img95046853_6.jpg GRAPHIC 21086
9 GRAPHIC img95046853_7.jpg GRAPHIC 70650
10 GRAPHIC img95046853_8.jpg GRAPHIC 566231
11 GRAPHIC img95046853_9.jpg GRAPHIC 512143
12 GRAPHIC img95046853_10.jpg GRAPHIC 137560
13 GRAPHIC img95046853_11.jpg GRAPHIC 119966
  Complete submission text file 0000950170-25-058060.txt   9731851

Data Files

Seq Description Document Type Size
14 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sage-20250421.xsd EX-101.SCH 14096
27 EXTRACTED XBRL INSTANCE DOCUMENT sage-20250421_htm.xml XML 674261
Mailing Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36544 | Film No.: 25867512
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)